Quantitative insights into effects of intrapartum antibiotics and birth mode on infant gut microbiota in relation to well-being during the first year of life

Birth interventions and infant gut microbiota

Katri Korpela^{a*}, Roosa Jokela^{a*}, Ching Jian^a, Evgenia Dikareva^a, Anne Nikkonen^b, Terhi Saisto^c, Kirsi Skogberg^d, Willem M. de Vos^{a,e}, *Kaija-Leena Kolho^{b,f} and Anne Salonen^{a#}

^aHuman Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; ^bChildren's Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland; ^cDepartment of Obstetrics and Gynecology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland; ^dClinic of Infectious Diseases, Jorvi and Helsinki University Hospital, Helsinki, Finland; ^eLaboratory of Microbiology, Wageningen University, Wageningen, the Netherlands; ^fTampere University, Tampere, Finland

*These authors contributed equally to this work

This research was supported by grants from Tekes 329/31/2015 (Health and the Early Life Microbiome (WMdV), Academy of Finland 1297765 (KK) and 1325103 (AS), Pediatric Research Foundation, Finland and Helsinki University Hospital Grant (KLK), The Paulo and Sohlberg Foundations (AS) and the Doctoral Program in Microbiology and Biotechnology, University of Helsinki, Finland funding (RJ).

Abbreviations:

AIC	Akaike information criterion
ANOVA	Analysis of variance
Cep	Cephalosporin
CRP	C-reactive protein

30	CS	C-section, Caesarean section
31	GBS	Group B Streptococcus
32	GI	Gastrointestinal
33	HELMi	Finnish Health and Early Life Microbiota
34	HMO	Human milk oligosaccharide
35	IP	Intrapartum
36	NGS	Next generation sequencing
37	PCoA	Principal coordinate analysis
38	Pen	Penicillin
39	rRNA	Ribosomal ribonucleic acid
40	SCFA	Short-chain fatty acids
41	VAS	Visual analogue scale
42	VD	Vaginal delivery
43	qPCR	Quantitative polymerase chain reaction

44

45

46 #Corresponding author: anne.salonen@helsinki.fi, Haartmaninkatu 3, PO box 21, FI-
47 00014, University of Helsinki, Helsinki, Finland

48

49 The authors have no conflicts to declare

50 Contributions:

51 Conceptualization: KS, KKK, AS, WMdV

52 Data curation: AN, RJ, ED

53 Formal Analysis: KK, RJ, CJ

54 Funding acquisition: WMdV, AS, KK, KKK

55 Investigation: ED, CJ, RJ, KK

56 Methodology: KK

57 Project administration: AS, TS, KKK, WMdV

58 Resources: AS, WMdV, TS, KKK

59 Software: KK, CJ, RJ

60 Supervision: AS, WMdV, KKK, KK

61 Validation: RJ, CJ, KK

62 Visualization: RJ, CJ, KK

63 Writing – original draft: RJ, KK, AS

64 Writing – review & editing: RJ, CJ, KK, KKK, WMdV, AS

65 The sequencing data will be deposited upon acceptance of the article to European

66 nucleotide Archive.

67

68

69 Abstract

70

71 Background and aims

72 Caesarean section (CS)-birth and maternally administered intrapartum antibiotics (IP)
73 affect colonization of the neonate. We compared the effects of CS delivery and IP
74 antibiotics on infant gut microbiota development and wellbeing over the first year. To
75 understand the developing community dynamics, we focused on absolute bacterial
76 abundance estimates over relative abundances.

77 Methods

78 We studied 144 healthy infants born between gestational weeks 37-42 vaginally without
79 antibiotics (N=58), with IP penicillin (N=25) or cephalosporin (N=13), or by CS with IP
80 cephalosporin (N=34) or other antibiotics (N=14). Gut microbiota composition and
81 temporal development was analysed at 5-7 time points during the first year of life using
82 16S rRNA gene amplicon sequencing, complemented with qPCR to obtain absolute
83 abundance estimates in 92 infants. A mediation analysis was carried out to identify taxa
84 linked to gastrointestinal function and discomfort (crying, defecation frequency and
85 signs of gastrointestinal symptoms) and birth interventions.

86 Results

87 Based on absolute abundance estimates, depletion of *Bacteroides* spp. was specific to
88 CS birth while decreased bifidobacteria and increased Bacilli were common to CS birth
89 and exposure to IP antibiotics in vaginal delivery. Abundance of numerous taxa differed
90 between the birth modes among cephalosporin-exposed infants. Penicillin had a milder
91 impact on the infant gut microbiota than cephalosporin. The effects of both CS birth and
92 IP antibiotics on infant gut microbiota associated with increased gastrointestinal
93 symptoms during the first months.

94

95 Conclusion

96 CS birth and maternal IP antibiotics have both specific and overlapping effects on infant
97 gut microbiota development. The resulting microbiota deviations were found to
98 associate with gastrointestinal symptoms in infancy.

99

100 Keywords: Early-life microbiota; antibiotics; caesarean section; birth route; 16S rRNA
101 gene amplicon sequencing; quantitative microbiota profiling

102

103

104 What You Need to Know:

105 Background and Context

106 Birth mode and maternal intrapartum antibiotics affect infant's gut microbiota
107 development but their relative contribution, and effects on absolute bacterial
108 abundances and infant health remain unknown.

109

110

111 **New Findings**

112 Utilizing quantitative microbiota profiling, we identified shared and unique microbiota
113 effects of birth mode and intrapartum antibiotics which explained up to 54% of
114 variation in parent-reported gastrointestinal symptoms in infants.

115

116 **Limitations**

117 Due to the limited sample sizes, especially during the first weeks of life, stratified
118 analyses according to antibiotic dosing could not be performed, and the results on
119 gastrointestinal symptom-microbiota-associations are tentative.

120

121 **Impact**

122 Birth mode overrules the effects of maternal antibiotics on infant microbiota
123 development, while both birth mode and maternal antibiotic use are associated to
124 common functional gastrointestinal symptoms in infancy.

125

126 **Lay summary:** Caesarean-section birth and maternal antibiotics during vaginal birth
127 affect infant's gut microbiota and may increase gastrointestinal discomfort.

128

129 **Introduction**

130

131 The human intestinal microbiota develops via successional stages during early life.¹ The
 132 infant's gut microbiota contributes to early immunological² and metabolic
 133 programming³ that affects host health later in life.⁴ Transmission of maternal microbes
 134 to the offspring during birth plays a major role in the initial colonization.^{1, 5, 6} The mode
 135 of birth is a major determinant of the neonates' initial microbial exposure; the assembly
 136 and dynamics of intestinal microbiota in infants born via caesarean section (CS) versus
 137 vaginal delivery (VD) differ substantially,^{1, 7} which has been suggested to mediate the
 138 negative long-term health outcomes related to CS birth.^{8, 9}

139

140 CS birth is not the only intervention impacting the neonate's early colonisation.
 141 Intrapartum (IP) antibiotic prophylaxis is routinely administered to mothers undergoing
 142 CS to reduce the risk of post-caesarean maternal infection. In vaginal deliveries
 143 approximately 25% of the mothers receive antibiotics to prevent neonatal group B
 144 Streptococcus (GBS) infection.¹⁰ Thus, antibiotics are used in a substantial number of
 145 deliveries in developed countries. Emerging evidence suggests that IP antibiotics
 146 influence the infant's microbiota development over a period of several months.¹¹⁻¹³

147

148 Previous studies utilizing next generation sequencing (NGS) have characterised the
 149 infant gut microbiota using relative bacterial abundance. However, quantitative analyses
 150 indicate that early microbiota development entails major quantitative changes both for
 151 the total bacterial load as well as on individual taxa,¹⁴ and the effects of birth
 152 interventions on absolute bacterial profiles are unknown.¹⁵ In addition, current studies
 153 addressing the health effects of IP on newborns have largely focused on neonatal GBS
 154 infection,^{16, 17} with first reports investigating their potential long-term effects on child
 155 health.¹⁸ We analysed the gut microbiota development in 144 healthy infants over the
 156 first year of life, focusing on 92 infants from whom qPCR- and NGS-based quantitative
 157 microbiota profiling¹⁹ data for absolute abundance estimation was available. The
 158 bacterial abundances were further associated with parallelly collected gastrointestinal
 159 (GI) and general health data. This approach enabled us to bypass the compositionality
 160 problem arising from relative abundances,²⁰ which may mask true community
 161 dynamics²¹ and lead to high false discovery rates.^{19, 22} We controlled for potential

162 confounding factors using a carefully selected cohort, aiming to disentangle the effect of
163 CS birth and IP antibiotics from potentially collinear effects.

164

165 **Materials and Methods**

166 **Study design**

167 Infants specifically recruited for this study (Jorvi cohort, N=68) and additional 83
168 infants recruited for the Finnish Health and Early Life Microbiota (HELMi) cohort²³
169 ([NCT03996304](https://clinicaltrials.gov/ct2/show/study/NCT03996304)) were included in the study. In both cases, pregnant women with
170 singleton gestation were recruited from the general population in Southern Finland.
171 Healthy babies, born on gestational weeks 37-42, without known congenital defects and
172 exceeding the birth weight of 2.5 kg were included in the study (except one baby with
173 birth weight of 2.4kg). At least one parent had to be Finnish speaking to be able to
174 answer the questionnaires.

175

176 For the Jorvi cohort, 31 mothers delivered with (vaginal deliveries N=26/31) and 37
177 without IP antibiotics (all vaginal deliveries). Infant faecal samples were collected on
178 day 1, 2, and 7, and at 1, 3, 6 and 12 months. From the HELMi cohort, 83 infants were
179 selected based on birth mode, IP antibiotics, and the availability of sequencing data
180 from infant's faecal samples at the age of 3 (considered as 1 month sample), and 6
181 weeks, and 3, 6, 9, and 12 months. From the combined cohort, five infants were
182 excluded as they received post-natal antibiotics prior to the first sampling point, and two
183 infants were excluded for low sequence quality, leaving a total of 144 infants.
184 Additionally, all samples following a post-natal antibiotic treatment were excluded from
185 the analysis as well as individual samples with low sequence quality (see Statistical
186 analysis). We divided the remaining infants into five study groups based on birth mode
187 and IP antibiotics: vaginally delivered (VD) reference group without IP antibiotics
188 (N=58), and four exposure groups: cefuroxime or cephalixin (cep) in CS (N=34), or in
189 VD (N=13), penicillin (pen) in VD (N=25), or in CS penicillin or any other antibiotics,
190 a combination of antibiotics or the antibiotic class not reported (CS-other, N=14) (Table
191 1). The CS groups comprised elective (N=23) and urgent (N=25) cases; all involved IP
192 antibiotics. Based on sample sufficiency, birth mode and sampling point the samples
193 from 92 infants were quantified for total bacteria by qPCR,¹⁹ representing 26 infants in

194 the reference group VD, 7 in VD-cep, 13 in VD pen, 33 in CS-cep, and 13 in CS-other
195 group.

196

197 Both cohort studies were approved by the ethical committee of The Hospital District of
198 Helsinki and Uusimaa and performed in accordance with the principles of the Helsinki
199 Declaration. Parents signed an informed consent at enrolment.

200

201 **Samples and data collection**

202 Parents collected faecal samples from the infants and stored them at -20°C. The samples
203 were transported frozen to the study centre within 6 months for -80°C storage. Data on
204 feeding regime, probiotic and antibiotic use, child health and growth were collected
205 with questionnaires (HELMi) or via phone interviews from the parents at the times of
206 stool sampling (Jorvi). Data on exposures *i.e.*, the mode of delivery and the usage, type
207 and dosing of maternal IP antibiotics were collected from hospital records for both
208 cohorts.

209

210 **Health outcomes**

211 Infant health and wellbeing were addressed using questionnaire data available for the
212 HELMi cohort. We used data from weekly to monthly repeating questionnaires using
213 the questionnaire closest to each faecal sampling. The variables included were related to
214 crying (hours per day and intensity estimated by a 0-100 mm visual analogue scale
215 (VAS), collected until six months, GI function (defecation rate, parent-perceived
216 stomach pain intensity and flatulence) until 9 months, and frequency of infections
217 estimated by the number of post-natal antibiotic courses by age of 12 months. Infant
218 growth was measured in postnatal care visits and transformed to age-dependent WHO
219 z-scores.²⁴

220

221 **Microbiota profiling**

222 Bacterial DNA was extracted from the faecal samples using a previously described bead
223 beating method²⁵ and KingFisher™ Flex automated purification system
224 (ThermoFisher Scientific, USA) as detailed in Supplementary methods. 16S rRNA gene
225 amplicon sequencing was performed using Illumina MiSeq and HiSeq platforms for
226 V3-V4 or V3 region as previously described,^{19, 26} respectively. In case of low DNA

yield or unsuccessful sequencing, the default library preparation protocol was modified as specified in Supplementary methods. The numeration of total bacteria was performed in triplicate as previously described.¹⁹ Bacterial DNA was quantified by amplifying 0.5 ng aliquots of each DNA extract with universal bacterial primers 331F/797R²⁷ targeting the 16S rRNA gene. The standard curves ranging from 10² to 10⁷ copies were constructed using the full-length amplicons of 16S rRNA gene of *Bifidobacterium bifidum* to convert the threshold cycle (Ct) values into 16S rRNA gene copy numbers per g of faeces.

The sequencing reads were processed using R package *mare*,²⁸ which relies on USEARCH²⁹ for quality filtering, chimera detection, and taxonomic annotation. Only the forward reads (V3), truncated to 150 bases, were used.³⁰ Reads occurring <10-50 times, depending on run size, were excluded as potentially erroneous. Taxonomic annotation was performed using USEARCH²⁹ by mapping the reads to the SILVA 16S rRNA reference database version 115,³¹ restricted to gut-associated taxa. Further, potential contaminants in the low-DNA-yield samples were filtered by removing reads appearing in negative controls (PCR or extraction blanks) in corresponding numbers from all samples. The absolute abundances were estimated and 16S rRNA gene copy-number corrected as previously described.¹⁹

Statistical analysis

After processing, the median number of reads obtained was 26 384 (range 3 to 253 458). Sufficient sequencing coverage was evaluated by comparing observed species richness to read count, and a cut-off of 2000 reads was chosen for HELMi samples, and 120 for Jorvi samples (to accommodate low-biomass samples from the first week of life). Samples with insufficient coverage (N=138, largely samples from the first week of life) and 69 samples with extremely high read counts from a single HiSeq run with high proportions of probable contaminants (mostly *Alcaligenaceae*)³² were excluded, leaving a total of 688 high-quality samples from 144 infants for downstream analyses, and 393 high-quality qPCR quantified samples from 92 infants.

259 The statistical analysis was conducted in R version 3.6.3 with the package *mare*,²⁸ with
 260 tools from packages *vegan*,³³ *MASS*,³⁴ and *nlme*³⁵, detailed in Supplementary methods.
 261 The association of antibiotic exposure (no antibiotic, penicillin, cephalosporin) and birth
 262 mode (vaginal or CS) with health outcomes was analysed at each faecal sampling until
 263 9 months using a negative binomial model adjusting for feeding type and probiotic use.
 264 To determine if the differences in health outcomes were mediated by changes in gut
 265 microbiota, the *PathModel* function in *mare*²⁸ was used to identify taxa predicting
 266 symptoms and the role of birth interventions related to the predictive taxa.

267

268 **Results**

269 **Study population**

270 An average of 4.9 samples (range 1-7) was collected per infant (Table 1) from the 144
 271 infants born by VD (N=96) or CS (N=48) during the first 12 months. The urgent and
 272 elective CSs were pooled for analysis (Supplementary results, Supplementary Figure 1).
 273 The IP antibiotics and doses varied among the delivery modes, with cefuroxime being
 274 the most common antibiotic used in CS and penicillin in VD (Table 2). Of all the VD
 275 antibiotics, 74% were solely prophylactic, of which 93% to prevent GBS transmission,
 276 and 7% due to premature rupture of membranes, while 69% of cephalosporins were
 277 therapeutic. Therapeutic IP antibiotics were administered due to fever or a rise in C-
 278 reactive protein (CRP) of the mother. Absolute bacterial profiles were calculated for a
 279 subset of 92 infants (VD: N=46, CS: N=46). Infant background statistics are
 280 summarised in Supplementary Table 1.

281

282

283 **The early development of the gut microbiota from birth to 12 months of age**

284

285 Birth mode or antibiotic exposure did not influence the total bacterial abundance
 286 quantified by qPCR at any given sampling time ($P>0.05$). Overall, the bacterial load
 287 increased with infant age in all groups, especially during the first weeks (Supplementary
 288 Figure 2).

289

290 To understand the temporal dynamics of the gut microbiota in infants, we analysed the
 291 average developmental trajectory of the 6 most abundant bacterial classes in infants

born by VD without antibiotics, comparing their relative (day 1 onwards) and absolute abundances (day 2 onwards) (Figure 1). Relative abundances show different community dynamics, such as a gradual decrease in the relative abundance of *Enterobacteriales* instead of the peak in absolute abundance around 20 weeks of age (Figure 1).

The overall developmental trajectories of the microbiota differed between the study groups categorized by delivery mode and antibiotic type (Table 1) in the ordination space using principal coordinate analysis (PCoA) (Figure 2). The temporal development of the gut microbiota followed a discernible pattern in the reference group (VD without antibiotics), and each exposure group showed a distinct developmental trajectory based on both absolute (Figure 2A) and relative data (Figure 2B). By 24 weeks, all but VD-cep converged with the reference group. The temporal trajectory of the gut microbiota in the VD-cep group markedly deviated from the reference group (Figure 2).

Impact of birth mode and intrapartum antibiotic on the temporal development of the gut microbiota using absolute data

To better understand the developing community dynamics, from this onwards we focused on the absolute abundance data. We first compared abundances of bacterial families and genera of the exposure groups to the reference (VD without antibiotic), adjusting for breastfeeding, probiotics, and the introduction of solids when relevant. The results observed at family level (Figure 3) were largely consistent at the genus level (Supplementary Figure 3).

In the first 3 months, the absolute abundance of *Bacteroidaceae* was significantly reduced in the CS, but not in the antibiotic-VD groups (fold change range 0.010-0.11, $P<0.01$ Figure 3). The depletion of *Bacteroidaceae* became statistically significant later, at 6 months and 9 months, in VD-cep (fold change 0.014, $P=0.0003$) and VD-pen (fold change 0.030, $P=0.01$).

Coriobacteriaceae (Actinobacteria) followed a pattern similar to that of *Bacteroidaceae*, being mainly associated with birth mode. The absolute abundance of *Bifidobacteriaceae* was strongly and negatively affected by both CS birth and by both cephalosporin and penicillin at 1 month, (fold change range 0.0040-0.18, $P<0.01$,

Figure 3) compared to VD without antibiotics. *Actinomycetaceae* and *Micrococcaceae* were enriched in all the exposure groups except the VD-pen group at one month (fold change range 6.2-13, $P<0.001$, Figure 3). Families in the Bacilli class, *Staphylococcaceae*, *Enterococcaceae*, *Lactobacillaceae*, and *Streptococcaceae*, were increased in absolute abundance in all exposure groups during the first 3 months (fold change range 1.0-240, $P<0.05$, Figure 3). The absolute abundances of several families in the classes Clostridia and Negativicutes were increased in all the exposure groups during the first month in comparison to the reference, with a few exceptions: reduced *Christensenellaceae* in the CS-other group at 1 month and in both CS groups at 6 weeks, reduced *Ruminococcaceae* in all but the VD-pen group at 1 and 3 months, and reduced *Acidaminococcaceae* in the CS groups at 4-6 weeks (Figure 3). The absolute abundances of Proteobacterial families in the antibiotic-exposed groups significantly deviated from the reference at multiple time points (fold change range 0.00054-6100, $P<0.05$, Figure 3).

Dissecting the effects of birth mode and intrapartum antibiotic on absolute levels of infant microbiota

We compared the birth modes while controlling for the IP antibiotic exposure, including only the cephalosporin-exposed CS and VD, to understand the effect of birth mode independently of antibiotic treatment, and *vice versa* (including only the vaginally born) (Supplementary Figures 4, 5). Several bacterial families differed in absolute abundance between the VD-cep and CS-cep groups, including enrichment of *Verrucomicrobiaceae* (3.8-fold difference, $P<0.001$ at 6 weeks), *Bifidobacteriaceae* (18 and 12-fold differences, $P<0.05$ at 1 and 3 months, respectively), *Streptomycetaceae* (7.0 and 62-fold differences, $P<0.001$ at 1 month and 9 months), *Lactobacillaceae* (8.3 and 12-fold differences, $P<0.05$ at 3 and 9 months), *Bacillaceae* (3.8 and 8.5-fold differences, $P<0.001$ at 6 weeks and 6 months), *Peptostreptococcaceae* (fold change range 7.5-5900, $P<0.01$ at 1, 3 and 6 months), *Lachnospiraceae* (20 and 99-fold differences, $P<0.01$ at 3 and 6 months), *Clostridiaceae* (23-fold difference, $P<0.001$ at 1 month), and *Christensenellaceae* (210-fold difference, $P<0.001$ at 6 months) in the CS-cep group. In contrast, *Bacteroidaceae* was reduced in CS-cep in comparison to VD-cep during months 1-3 (fold change 0.07, $P<0.01$ at 6 weeks).

In terms of the effect of antibiotic types in the vaginally born infants, increased absolute abundances were found in *Verrucomicrobiaceae* and *Rikenellaceae* (22 and 79-fold differences, $P<0.001$ at 6 weeks), *Bifidobacteriaceae* and *Lactobacillaceae* (25 and 5.2-fold differences, $P<0.01$ at 3 months), *Coriobacteriaceae* (fold change range 6.0-910, $P<0.001$ at 1-3 months), *Peptostreptococcaceae* (94 and 72-fold differences, $P<0.05$ at 1 and 6 months), *Christensenellaceae* (8300-fold difference, $P<0.001$ at 6 months), *Bacillaceae* (36 and 13-fold differences, $P<0.001$ at 6 weeks and 6 months) in the VD-cep group compared to VD-pen. Members of *Clostridiaceae* were consistently reduced in VD-pen in comparison to VD-cep at 1 month (fold change 0.34, $P<0.001$).

Health outcomes

To determine whether the mode of delivery and IP antibiotics were associated with the infants' health during the first year of life, we compared the study groups in terms of health variables from the HELMi questionnaires pertinent to parent-reported digestive and overall health (Figure 4). All exposure groups showed increased GI symptoms mainly during the first 3 months compared to the reference group VD. There were significant differences in defecation rate, crying intensity, duration of crying per day, parent-perceived stomach pain intensity, and flatulence between the study groups (Figure 4). Infants' overall health as reported by the parents did not differ between the study groups at any sampling age (ANOVA: $P>0.1$), nor did the cumulative number of antibiotic courses by 12 months ($P=0.81$) nor infant weights at birth or at 12 months (ANOVA, $P\geq 0.25$, Supplementary Table 1).

Week 4

We assessed the hypothesis that the differences in the gut microbiota mediate the GI symptoms by performing a mediation analysis on the symptoms at time points that showed significant differences between the study groups (Figure 4) in infants with absolute data available (Supplementary Table 2). We analysed the association between antibiotic exposure and birth mode as separate variables with the health outcomes, compared the study groups in terms of the health outcomes, and identified bacterial taxa associated with both the health outcomes and the antibiotic exposure or birth mode. At 4 weeks, cephalosporin exposure (including both vaginal birth and CS) was significantly and positively associated with crying intensity ($P=0.009$), and when comparing groups,

the VD-cep group had increased crying intensity in comparison to the reference group ($P=0.009$). A model using absolute bacterial abundances explained 24% of the variation in crying intensity (Figure 5a). The association of cephalosporin exposure with crying intensity appeared to be mediated by the low abundance of *Bacteroides* associated with cephalosporin exposure. Defecation rate was positively associated with cephalosporin exposure ($P<0.0001$) and CS ($P<0.0001$), and the CS-cep group had elevated defecation rate ($P<0.0001$) compared to the reference group. The bacterial composition explained 28% of the variation in defecation rate. The increased defecation rate in the CS-born and cephalosporin-exposed infants compared to the controls appeared attributable to the decreased abundances of *Bacteroides* and uncultured *Veillonellaceae* (Figure 5a).

Week 6

At 6 weeks, defecation rate was elevated in the CS-cep group ($P=0.007$) compared to the reference, and both CS birth ($P=0.006$) and cephalosporin exposure ($P=0.01$) were independently associated with increased defecation rate. The gut microbiota composition was associated with defecation rate, explaining 51% of the variation. The effects of CS birth and cephalosporin appeared to be mediated by the decreased abundances of *Bifidobacterium* and *Fingoldia* (Figure 5b). Stomach pain intensity was significantly elevated in the CS-cep ($P=0.009$) and VD-cep ($P=0.01$) groups compared to the reference. Cephalosporin exposure was significantly associated with stomach pain ($P=0.005$). The association was mediated by the reduced abundance of *Collinsella* and the increased abundances of *Escherichia* and *Streptococcus* in the CS-born and cep-exposed infants (Figure 5b). Gut microbiota composition explained 30% of the variation in stomach pain intensity.

Week 12

At 12 weeks, stomach pain intensity was increased in the CS-cep group ($P=0.04$) and VD-cep group ($P=0.02$) compared to the reference. Cephalosporin exposure was significantly associated with the pain intensity ($P=0.02$). The gut microbiota explained 46% of the variation in stomach pain, the low absolute abundance of *Alistipes* and high abundance of *Roseburia* being linked with both CS birth and stomach pain (Figure 5c). Flatulence intensity was increased in the CS-cep group ($P=0.02$) compared to the reference, and CS birth ($P=0.05$) and cephalosporin exposure ($P=0.02$) were associated

with increased flatulence intensity. The gut microbiota explained 23% of the variation in flatulence intensity at 12 weeks. The association of CS birth and cephalosporin and flatulence appeared mediated by the reduced abundance of *Bacteroides* and *Alistipes* (Figure 5c).

Week 24

At 24 weeks, stomach pain intensity was associated with penicillin exposure ($P=0.01$) and increased in the VD-pen group ($P=0.01$) compared to the reference. Gut microbiota composition explained 54% of the variation in stomach pain intensity, with *Paludibacter* mediating the association with penicillin exposure (Figure 5d).

Discussion

We set out to study how the temporal quantitative and compositional gut microbiota development is influenced by the mode of delivery versus exposure to delivery antibiotics, and whether these early exposures and associated differences in early microbiota composition relate to common gastrointestinal symptoms in infants. Whereas CS delivery had profound effects on the gut microbiota, we observed that maternal IP antibiotics compromised the colonisation of the newborn's gut microbiota independent of the birth mode. Notably, the decreased absolute abundance of *Bifidobacterium* and increased abundance of Bacilli characterised both CS-deliveries and IP antibiotic exposed vaginally delivered infants, whereas reduction of *Bacteroides* was mainly seen after CS delivery. Moreover, we observed that the changes in gut microbiota taxa associated to CS birth and IP antibiotic exposure were further associated with increased GI symptoms.

This is one of the first studies using quantitative microbiota profiling^{19, 36} for community-wide absolute abundance estimates of infants' indwelling gut bacteria and the first to address the associated GI health. The vast majority of existing NGS studies on human microbiota utilize only relative abundance. This has been recently shown to under- or overestimate temporal changes of the gut microbiota in preterm infants,²¹ especially concerning Proteobacteria such as *Escherichia coli* and *Klebsiella*. Several members within Proteobacteria, such as *E. coli*, possess flexible metabolic capacity³⁷ and fast replication rate and therefore have high temporal variation in cell density. In the

present study, we documented a decreasing developmental trajectory of the most abundant Proteobacterial order *Enterobacteriales* in relative abundance data, in line with earlier relative abundance studies.³⁸ In contrast, the absolute abundance of *Enterobacteriales* increased over the first 6 months of life, peaking around the time of introducing complementary foods, in agreement with a previous study in term infants utilizing targeted qPCR.³⁹ The developmental patterns of other dominant bacteria are largely in concordance with the previous qPCR-based study, showing a general upward trend in the first few months of life.³⁹ Relative abundances also underestimate taxa with low 16S rRNA gene copy numbers, such as *Bifidobacteriales* (mean 3.5 copies⁴⁰) compared to taxa with high copy numbers, such as *Clostridiales* (mean 5.5 copies⁴⁰), observed also in this study.

CS birth has been suggested to cause microbial deprivation, a lack of microbial colonisation in early life. This was not the case in our study, as CS-born and antibiotic-exposed infants were colonised with comparable total bacterial loads per gram of faeces as the non-exposed vaginally born group. We observed a clear age-driven increase in the bacterial loads in all study groups using qPCR. Unfortunately, majority of the low bacterial biomass samples from the first week of life had insufficient amount of faecal sample to allow quantitative analyses. Previous studies have reported lower bacterial loads in CS born infants,⁴¹ and a faster age-driven increase in bacterial quantities in the stools of CS born infants.⁴² It is nevertheless possible that the transient difference in total microbial load occurring before 3 weeks of age was not detected in the present study.

Relative abundance studies have consistently documented an altered bacterial signature in gut microbiota of CS born infants,¹ recently shown to be restored by maternal FMT.⁴³ Most studies on infant microbiota in relation to birth mode have neglected the fact that practically all CS births involve IP antibiotics, making it impossible to isolate the effects of IP versus the birth route.⁴⁴ Our results comparing the effect of birth mode under the exposure to the same antibiotic, cephalosporin, confirm that birth mode *per se* influences the infant gut microbiota. CS birth usually involves the administration of cephalosporin, while in VD, the most commonly used IP antibiotic is penicillin.⁴⁵ It should be noted that the use of cephalosporin in VD typically indicates

therapeutic rather than prophylactic use, and in our cohort, every other cep-VD mother received multiple doses compared to the single prophylactic dose used in CS. Hence, in clinical settings, labours with different IP antibiotics may also differ for other factors than the antibiotic exposure. A recent randomized trial documented a lack of clear differences in the gut microbiota of CS-born infants exposed versus unexposed to IP antibiotic.⁴⁵ In conclusion, our study and earlier data indicate that the mode of birth is the major factor affecting neonatal colonisation, in line with CS eliminating the contact between the infant and maternal gut bacteria, preventing their transmission at birth.⁴⁶ Infants born by elective CS, in the absence of labour and rupture of membranes, are believed to be the most deprived from the vertically transmitted microbes. A recent study however contradicted this hypothesis,⁴⁷ which we corroborated by showing the negligible differences in the infant microbiota between the elective and urgent CS deliveries.

503

In contrast, in VD infants the IP antibiotic plays a major role. We showed that the impact of IP antibiotic exposure during vaginal birth on the gut microbiota was largely similar to the effect of CS delivery on the infant gut microbiota. However, we were able to identify several distinct effects of birth mode and antibiotic exposure. Namely, the early absolute abundances of *Bacteroidaceae*, *Coriobacteriaceae* and *Burkholderiaceae* were reduced by CS birth but not by IP antibiotics, while *Ruminococcaceae*, *Porphyromonadaceae*, *Rikenellaceae*, and *Pasteurellaceae* abundances were negatively affected by both CS birth and antibiotics. *Bifidobacteriaceae* was most strongly affected by the antibiotic exposure. These observations recapitulate and expand the results of a recent Japanese study⁴⁸ and Canadian studies.⁴⁹ With absolute data, we found the effect of IP antibiotics in VD infants to peak at 3 months with some differences persisting up to 12 months. Previous studies using relative microbiota data have reported the effect of birth-related antibiotics to resolve after 3 months,⁴⁷ however, most of the studies do not extend over this age.¹³ A recent prospective study on 100 vaginally born infants reported the effect of IP antibiotics to overrule those of post-natal antibiotics on the infant microbiota, and persist until the at age of one year.⁵⁰

520

Importantly, several bacterial taxa were increased in absolute abundance in the CS-born and in the antibiotic exposed infants. For example, IP antibiotic exposure in VD, and

CS birth both resulted in the overgrowth of streptococci as well as staphylococci and enterococci. This is likely due to reduced colonization resistance resulting from the depletion of bifidobacteria, which have anti-streptococcal activity.⁵¹ In fact, the majority of bacterial taxa affected by IP antibiotics, except bifidobacteria, were increased in absolute abundance during the first month. This suggests that the major driver of microbial changes after exposure to IP antibiotic is not the antibiotic itself, but the antibiotic-induced reduction in bifidobacteria. Since the direct effects by the IP antibiotic on the infant are short (from hours to couple of days), the lasting effects likely reflect the consequences of the fundamental alteration in the ecosystem assembly.⁵² The pattern is somewhat different after CS birth, where diverse members of the microbiota, including *Bacteroides*, bifidobacteria and members of Clostridiales and Negativicutes, were likely directly reduced due to lower mother-infant microbiota transmission rates in CS birth.⁷

To our knowledge, our study is the first to evaluate the influence of birth mode and associated maternal antibiotic administration in parallel with the infant gut microbiota and functional GI symptoms. Previously, CS birth and postnatal antibiotics have been identified as risk factors for functional GI disorders in pre- and full-term infants.⁵³ In our study, CS-born and VD IP antibiotic-exposed infants experienced more parent-reported abdominal discomfort and crying compared to VD infants with no antibiotics in the first month of life, while their general health and growth was comparable. According to the mediation analysis, the CS-associated reduction in the abundance of *Bacteroides* and its relatives was linked to increased defecation rates and crying intensity at 1 month, and increased flatulence and stomach pain at 3 months compared to the reference. The cephalosporin-associated decline in *Bifidobacterium* and *Collinsella* was associated with increased defecation rate and stomach pain at 6 weeks compared to the reference. Colic symptoms have previously been linked with the reduced relative abundance of bifidobacteria^{54, 55} and to an altered balance between H₂-producing and -utilising taxa.⁵⁶ Overall, the models based on absolute bacterial abundances explained 23-54% of the infants' GI symptom variation, which is remarkable considering that the origin and underlying reasons of functional GI symptoms in infants often remain unclear.⁵⁷ These results are preliminary and derived from a relatively small study, and hence need validation in future cohorts.

556

557 *Bacteroides* and bifidobacteria are the major human milk oligosaccharide (HMO) -
558 degraders and thus keystone taxa in the breastfed infant gut,⁵⁸⁻⁶⁰ so their depletion will
559 have profound impact on the metabolic capacity and processes in the infant gut.⁶¹
560 Reduced conversion of HMOs into short-chain fatty acids (SCFA) increases gut pH,^{62, 63}
561 and alters trophic interactions and metabolic outputs of the gut microbiota. Such
562 changes likely affect gut physiology and function and may favour bacteria that normally
563 are less abundant in the infant gut, such as members of Clostridia, which in the present
564 study were associated with increased defecation rates, flatulence, and stomach pain.

565

566 There is some uncertainty as to how long the microbiota differences persist after CS
567 birth or IP antibiotic exposure, and how the persistence affects host physiology. Studies
568 based on relative abundance data have shown a convergence to vaginally born controls
569 during 6-12 months.^{11, 64} Long-term studies on the effects of IP antibiotic exposure have
570 not been conducted. Our findings suggest that several birth-mode and IP antibiotic-
571 related microbial signatures are still detectable at 12 months, although the major
572 differences subside by 6 months. There may be individual differences regarding the
573 normalisation of the gut microbiota after CS birth or antibiotic exposure, possibly
574 related to diet, probiotic use, and other practices.^{65, 66} A recent Danish study showed that
575 increased asthma risk was found in children born by CS only if their gut microbiota
576 composition at 1 year of age still retained a CS-birth-related microbial signature,⁹ while
577 animal experiments showcase that even a transient early microbiota disruption is
578 sufficient to lead to persistent functional and even structural alterations in the immune
579 system.⁶⁷

580

581 Together, CS and antibiotic exposure at birth affect a substantial proportion of infants
582 worldwide. Our data suggest that their effects on early colonisation of the gut
583 microbiota may cause elevated levels of pain and discomfort in the infant during the
584 first months of life, while a recent study found no association between IP antibiotics and
585 childhood allergies.¹⁸ These studies are important primers for filling the knowledge
586 gaps that underlie the lack of consensus for the choice between universal or risk-based
587 screening for IP antibiotic use,¹⁰ and contribute to weighing the benefits and potential
588 harms of antibiotic use in mothers and infants.

589

590 Acknowledgements

591

592 This research was supported by grants from Tekes 329/31/2015 (Health and the Early
593 Life Microbiome (WMdV), Academy of Finland 1297765 (KK) and 1325103 (AS),
594 Pediatric Research Foundation, Finland and Helsinki University Hospital Grant (KLK),
595 The Paulo and Sohlberg Foundations (AS) and the Doctoral Program in Microbiology
596 and Biotechnology, University of Helsinki, Finland funding (RJ). We thank Tinja
597 Kanerva for processing the samples and Jessica Manngård for assistance with the
598 questionnaire data analysis and Tytti Jaakkola, MD for recruiting some of the patients in
599 the Jorvi cohort.

600

601 REFERENCES

- 602 1. Korpela K, de Vos WM. Early life colonization of the human gut: microbes
603 matter everywhere. *Curr Opin Microbiol* 2018;44:70-78.
- 604 2. Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its
605 impact on health in later life. *Allergology International* 2017.
- 606 3. Cox LM, Yamanishi S, Sohn J, et al. Altering the intestinal microbiota during a
607 critical developmental window has lasting metabolic consequences. *Cell*
608 2014;158:705-721.
- 609 4. Cox LM, Yamanishi S, Sohn J, et al. Altering the intestinal microbiota during a
610 critical developmental window has lasting metabolic consequences. *Cell*
611 2014;158:705-721.
- 612 5. Bäckhed F, Roswall J, Peng Y, et al. Dynamics and Stabilization of the Human
613 Gut Microbiome during the First Year of Life. *Cell Host Microbe* 2015;17:690-
614 703.
- 615 6. Yassour M, Jason E, Hogstrom LJ, et al. Strain-Level Analysis of Mother-to-
616 Child Bacterial Transmission during the First Few Months of Life. *Cell Host &*
617 *Microbe* 2018;24:146-154.e4.
- 618 7. Shao Y, Forster SC, Tsaliki E, et al. Stunted microbiota and opportunistic
619 pathogen colonization in caesarean-section birth. *Nature* 2019;574:117-121.
- 620 8. Stiemsma LT, Michels KB. The Role of the Microbiome in the Developmental
621 Origins of Health and Disease. *Pediatrics* 2018;141:e20172437.
- 622 9. Stokholm J, Thorsen J, Blaser MJ, et al. Delivery mode and gut microbial
623 changes correlate with an increased risk of childhood asthma. *Science*
624 *Translational Medicine* 2020;12:eaax9929.
- 625 10. Le Doare K, Heath PT, Plumb J, et al. Uncertainties in Screening and Prevention
626 of Group B Streptococcus Disease. *Clin Infect Dis* 2019;69:720-725.
- 627 11. Dierikx TH, Visser DH, Benninga MA, et al. The influence of prenatal and
628 intrapartum antibiotics on intestinal microbiota colonisation in infants: A
629 systematic review. *Journal of Infection* 2020.
- 630 12. Tapiainen T, Koivusaari P, Brinkac L, et al. Impact of intrapartum and postnatal
631 antibiotics on the gut microbiome and emergence of antimicrobial resistance in
632 infants. *Sci Rep* 2019;9:10635.
- 633 13. Zimmermann P, Curtis N. Effect of intrapartum antibiotics on the intestinal
634 microbiota of infants: a systematic review. *Archives of Disease in Childhood -*
635 *Fetal and Neonatal Edition* 2020;105:201.
- 636 14. Penders J, Thijs C, Vink C, et al. Factors Influencing the Composition of the
637 Intestinal Microbiota in Early Infancy. *Pediatrics* 2006;118:511.
- 638 15. Jian C, Carpen N, Helve O, et al. Early-life gut microbiota and its connection to
639 metabolic health in children: Perspective on ecological drivers and need for
640 quantitative approach. *EBioMedicine* 2021;69.
- 641 16. McLaren RA, Atallah F, Minkoff H. Antibiotic Prophylaxis Trials in Obstetrics:
642 A Call for Pediatric Collaboration. *AJP Rep* 2020;10:e155-e158.
- 643 17. Russell NJ, Seale AC, O'Sullivan C, et al. Risk of Early-Onset Neonatal Group
644 B Streptococcal Disease With Maternal Colonization Worldwide: Systematic
645 Review and Meta-analyses. *Clinical Infectious Diseases* 2017;65:S152-S159.

- 646 18. Dhudasia MB, Spergel JM, Puopolo KM, et al. Intrapartum Group B
647 Streptococcal Prophylaxis and Childhood Allergic Disorders. *Pediatrics*
648 2021;147.
- 649 19. Jian C, Luukkonen P, Yki-Järvinen H, et al. Quantitative PCR provides a simple
650 and accessible method for quantitative microbiota profiling. *PLOS ONE*
651 2020;15:e0227285.
- 652 20. Jackson DA. Compositional data in community ecology: The paradigm or peril
653 of proportions? *Ecology* 1997;78:929-940.
- 654 21. Rao C, Coyte KZ, Bainter W, et al. Multi-kingdom ecological drivers of
655 microbiota assembly in preterm infants. *Nature* 2021;591:633-638.
- 656 22. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, et al. Microbiome Datasets Are
657 Compositional: And This Is Not Optional. *Frontiers in Microbiology* 2017;8.
- 658 23. Korpela K, Dikareva E, Hanski E, et al. Cohort profile: Finnish Health and Early
659 Life Microbiota (HELMi) longitudinal birth cohort. *BMJ Open* 2019;9:e028500.
- 660 24. Ebrahim GJ. WHO Child Growth Standards. Growth Velocity Based on Weight,
661 Length and Head Circumference. *Methods and Development. Journal of Tropical*
662 *Pediatrics* 2010;56:136-136.
- 663 25. Salonen A, Nikkilä J, Jalanka-Tuovinen J, et al. Comparative analysis of fecal
664 DNA extraction methods with phylogenetic microarray: effective recovery of
665 bacterial and archaeal DNA using mechanical cell lysis. *J Microbiol Methods*
666 2010;81:127-34.
- 667 26. Milani C, Hevia A, Foroni E, et al. Assessing the Fecal Microbiota: An
668 Optimized Ion Torrent 16S rRNA Gene-Based Analysis Protocol. *PLOS ONE*
669 2013;8:e68739.
- 670 27. Nadkarni MA, Martin FE, Jacques NA, et al. Determination of bacterial load by
671 real-time PCR using a broad-range (universal) probe and primers set.
672 *Microbiology (Reading)* 2002;148:257-266.
- 673 28. Korpela K. *mare: Microbiota Analysis in R Easily*. R package version 1.0 ed,
674 2016.
- 675 29. Edgar RC. Search and clustering orders of magnitude faster than BLAST.
676 *Bioinformatics* 2010;26:2460-2461.
- 677 30. Korpela K, Blakstad EW, Moltu SJ, et al. Intestinal microbiota development and
678 gestational age in preterm neonates. *Scientific Reports* 2018;8:2453.
- 679 31. Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database
680 project: improved data processing and web-based tools. *Nucleic acids research*
681 2013;41:D590-D596.
- 682 32. Salter SJ, Cox MJ, Turek EM, et al. Reagent and laboratory contamination can
683 critically impact sequence-based microbiome analyses. *BMC Biology*
684 2014;12:87.
- 685 33. Jari Oksanen FGB, Michael, Friendly, Roeland Kindt, Pierre Legendre, Dan,
686 McGlinn, Peter R. Minchin, R. B. O'Hara, Gavin L., Simpson, Peter Solymos,
687 M. Henry H. Stevens, Eduard, Szocs, Helene Wagner. *vegan: Community*
688 *Ecology Package*. R package version 2.5-6 ed, 2019.
- 689 34. Venables WNR, B. D. *Modern Applied Statistics with S*. Volume Fourth
690 Edition. New York: Springer, 2002.
- 691 35. Pinheiro J BD, DebRoy S, Sarkar D, R Core Team,. *nlme: Linear and Nonlinear*
692 *Mixed Effects Models*. R package version 3.1-144 ed, 2020.
- 693 36. Vandeputte D, Kathagen G, D'hoë K, et al. Quantitative microbiome profiling
694 links gut community variation to microbial load. *Nature* 2017;551:507-511.

- 695 37. Bradley PH, Pollard KS. Proteobacteria explain significant functional variability
696 in the human gut microbiome. *Microbiome* 2017;5:36-36.
- 697 38. Yassour M, Vatanen T, Siljander H, et al. Natural history of the infant gut
698 microbiome and impact of antibiotic treatment on bacterial strain diversity and
699 stability. *Sci Transl Med* 2016;8:343ra81.
- 700 39. Obermajer T, Grabnar I, Benedik E, et al. Microbes in Infant Gut Development:
701 Placing Abundance Within Environmental, Clinical and Growth Parameters. *Sci*
702 *Rep* 2017;7:11230.
- 703 40. Stoddard SF, Smith BJ, Hein R, et al. rrnDB: improved tools for interpreting
704 rRNA gene abundance in bacteria and archaea and a new foundation for future
705 development. *Nucleic Acids Res* 2015;43:D593-8.
- 706 41. Selma-Royo M, Calatayud Arroyo M, García-Mantrana I, et al. Perinatal
707 environment shapes microbiota colonization and infant growth: impact on host
708 response and intestinal function. *Microbiome* 2020;8:167.
- 709 42. Martin R, Makino H, Cetinyurek Yavuz A, et al. Early-Life Events, Including
710 Mode of Delivery and Type of Feeding, Siblings and Gender, Shape the
711 Developing Gut Microbiota. *PloS one* 2016;11:e0158498-e0158498.
- 712 43. Korpela K, Helve O, Kolho KL, et al. Maternal Fecal Microbiota
713 Transplantation in Cesarean-Born Infants Rapidly Restores Normal Gut
714 Microbial Development: A Proof-of-Concept Study. *Cell* 2020;183:324-334.e5.
- 715 44. Nogacka AM, Salazar N, Arboleya S, et al. Early microbiota, antibiotics and
716 health. *Cell Mol Life Sci* 2018;75:83-91.
- 717 45. Kamal SS, Hyldig N, Krych Ł, et al. Impact of Early Exposure to Cefuroxime
718 on the Composition of the Gut Microbiota in Infants Following Cesarean
719 Delivery. *The Journal of Pediatrics* 2019;210:99-105.e2.
- 720 46. Korpela K, Costea P, Coelho LP, et al. Selective maternal seeding and
721 environment shape the human gut microbiome. *Genome research* 2018;28:561-
722 568.
- 723 47. Azad MB, Konya T, Persaud RR, et al. Impact of maternal intrapartum
724 antibiotics, method of birth and breastfeeding on gut microbiota during the first
725 year of life: a prospective cohort study. *Bjog* 2016;123:983-93.
- 726 48. Imoto N, Kano C, Aoyagi Y, et al. Administration of β -lactam antibiotics and
727 delivery method correlate with intestinal abundances of Bifidobacteria and
728 Bacteroides in early infancy, in Japan. *Scientific reports* 2021;11:6231-6231.
- 729 49. Chen YY, Zhao X, Moeder W, et al. Impact of Maternal Intrapartum
730 Antibiotics, and Caesarean Section with and without Labour on Bifidobacterium
731 and Other Infant Gut Microbiota. *Microorganisms* 2021;9:1847.
- 732 50. Ainonen S, Tejesvi MV, Mahmud MR, et al. Antibiotics at birth and later
733 antibiotic courses: effects on gut microbiota. *Pediatric Research* 2021.
- 734 51. Aloisio I, Mazzola G, Corvaglia LT, et al. Influence of intrapartum antibiotic
735 prophylaxis against group B Streptococcus on the early newborn gut
736 composition and evaluation of the anti-Streptococcus activity of
737 Bifidobacterium strains. *Appl Microbiol Biotechnol* 2014;98:6051-60.
- 738 52. Sprockett D, Fukami T, Relman DA. Role of priority effects in the early-life
739 assembly of the gut microbiota. *Nat Rev Gastroenterol Hepatol* 2018;15:197-
740 205.
- 741 53. Salvatore S, Baldassarre ME, Di Mauro A, et al. Neonatal Antibiotics and
742 Prematurity Are Associated with an Increased Risk of Functional

Gastrointestinal Disorders in the First Year of Life. *The Journal of Pediatrics* 2019;212:44-51.

54. de Weerth C, Fuentes S, Puylaert P, et al. Intestinal microbiota of infants with colic: development and specific signatures. *Pediatrics* 2013;131:e550-8.

55. Pärty A, Kalliomäki M, Endo A, et al. Compositional Development of Bifidobacterium and Lactobacillus Microbiota Is Linked with Crying and Fussing in Early Infancy. *PLoS One* 2012;7.

56. Pham VT, Lacroix C, Braegger CP, et al. Lactate-utilizing community is associated with gut microbiota dysbiosis in colicky infants. *Scientific Reports (Nature Publisher Group)* 2017;7:1-13.

57. Vandenplas Y, Hauser B, Salvatore S. Functional Gastrointestinal Disorders in Infancy: Impact on the Health of the Infant and Family. *Pediatric gastroenterology, hepatology & nutrition* 2019;22:207-216.

58. Lawson MAE, O'Neill JJ, Kujawska M, et al. Breast milk-derived human milk oligosaccharides promote Bifidobacterium interactions within a single ecosystem. *The ISME Journal* 2020;14:635-648.

59. Marcobal A, Barboza M, Sonnenburg ED, et al. Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. *Cell Host Microbe* 2011;10:507-14.

60. Ward RE, Niñonuevo M, Mills DA, et al. In vitro fermentation of breast milk oligosaccharides by Bifidobacterium infantis and Lactobacillus gasseri. *Appl Environ Microbiol* 2006;72:4497-9.

61. Coppa GV, Gabrielli O, Pierani P, et al. Changes in carbohydrate composition in human milk over 4 months of lactation. *Pediatrics* 1993;91:637-41.

62. Duar RM, Kyle D, Casaburi G. Colonization Resistance in the Infant Gut: The Role of B. infantis in Reducing pH and Preventing Pathogen Growth. *High Throughput* 2020;9.

63. Henrick BM, Hutton AA, Palumbo MC, et al. Elevated Fecal pH Indicates a Profound Change in the Breastfed Infant Gut Microbiome Due to Reduction of Bifidobacterium over the Past Century. *mSphere* 2018;3:e00041-18.

64. Rutayisire E, Huang K, Liu Y, et al. The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants' life: a systematic review. *BMC Gastroenterol* 2016;16:86.

65. Korpela K, Salonen A, Hickman B, et al. Fucosylated oligosaccharides in mother's milk alleviate the effects of caesarean birth on infant gut microbiota. *Scientific Reports* 2018;8:13757.

66. Korpela K, Salonen A, Vepsäläinen O, et al. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. *Microbiome* 2018;6:182.

67. Gensollen T, Iyer SS, Kasper DL, et al. How colonization by microbiota in early life shapes the immune system. *Science* 2016;352:539-44.

Table 1 Faecal samples analysed per delivery group and age (relative data /absolute data).

	VD	VD-cep	VD-pen	CS-cep	CS-other
1 day	11/0	1/0	4/0	2/0	0/0
2 days	23/4	2/0	7/5	5/2	2/1
1 week	31/1	3/0	13/0	7/0	0/0
1 month	46/25	12/7	23/12	33/32	13/13
6 weeks	20/20	10/7	10/8	25/25	12/12
3 months	41/20	12/7	22/8	31/27	13/12
6 months	48/22	12/6	24/12	32/30	13/12
9 months	16/16	7/4	9/7	20/20	10/8
12 months	36/3	8/0	15/3	12/4	3/1

VD = vaginal delivery, cep = cephalosporin, pen = penicillin, CS = Caesarean section

Table 2 Intrapartum antibiotics and doses by delivery group among the 144 infants (relative data / absolute data).

Birth mode	antibiotic	1 dose	2 or more doses	Total count of infants
VD	penicillin	4/1	21/12	25/13
	cefuroxime	8/3	5/4	13/7
Elective CS	cefuroxime	13/12		13/12
	cephalexin	7/7		7/7
	clindamycin	1/1		1/1
	metronidazole	1/1		1/1
	not reported	1/1		1/1
Urgent CS	cefuroxime	10/10	1/1	11/11
	cephalexin	3/3		3/3
	clindamycin	2/2	2/2	4/4
	penicillin		2/1	2/1
	combination	1/1	4/4	5/5

VD = vaginal delivery, CS = Caesarean section.

Figure 1 Temporal development of six most abundant bacterial classes in absolute (A) and relative (B) abundance in vaginally born infants not exposed to antibiotics. The lines show means with 50% confidence interval.

Figure 2 Principal coordinates analysis of the species-level absolute (A) and relative (B) abundances. Distances calculated based on Pearson correlations. The samples are coloured by treatment group and the mean component scores of the groups by age (weeks) presented by large circles.

Figure 3 Fold changes calculated using absolute abundances of bacterial families with at least one group significantly differing from the reference group (VD) in the taxon-wise comparisons between all delivery groups. VD: vaginal delivery without antibiotic, VD-cep: vaginal delivery with cephalosporin, VD-pen: vaginal delivery with penicillin, CS-cep: C-section with cephalosporin, CS-other: C-section with any other antibiotic; FC: fold change (cut-off at 5 and 0.001 for clarity); *: $P < 0.05$, **: $P < 0.01$, ***: $P < 0.001$, in all cases FDR < 0.1.

808
 809 Figure 4 Parent-reported health outcomes at faecal sampling points from 1 to 6 by delivery group. *: $P < 0.05$, **: $P < 0.01$, ***: $P < 0.001$
 810

811
 812 Figure 5. Associations between birth interventions, absolute abundances of bacteria, and GI symptoms at
 813 4 weeks (a), 6 weeks (b), 12 weeks (c) and 24 weeks (d). The amount of variation explained by the
 814 bacteria shown is given as percentage. The models were selected based on Akaike information criterion
 815 (AIC). In some cases, the final model retained variables that were not statistically significant but
 816 contributed significantly to the model.

817

Flatulence
intensity (0–100)

Stomach ache
intensity (0–100)

Defecation rate
per week

Hours of
crying per day

Group

- Vaginal delivery no antibiotics
- Vaginal delivery with cephalosporin
- Vaginal delivery with penicillin
- C-section with cephalosporin
- C-section with other antibiotic

a

b

c

d